CA2271847A1 - Process for the preparation of salts and esters of clavulanic acid - Google Patents
Process for the preparation of salts and esters of clavulanic acid Download PDFInfo
- Publication number
- CA2271847A1 CA2271847A1 CA002271847A CA2271847A CA2271847A1 CA 2271847 A1 CA2271847 A1 CA 2271847A1 CA 002271847 A CA002271847 A CA 002271847A CA 2271847 A CA2271847 A CA 2271847A CA 2271847 A1 CA2271847 A1 CA 2271847A1
- Authority
- CA
- Canada
- Prior art keywords
- clavulanic acid
- amine
- clavulanate
- addition
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
An improved process for the preparation of pharmaceutically acceptable alkali metal salts or esters of clavulanic acid has been provided for. Furthermore, also potassium clavulanate with an extremely low amine content and pharmaceutical compositions comprising the same have been provided for.
Description
PROCESS FOR THE PREPARATION OF SALTS AND ESTERS
OF CLAW'LANIC ACID
s The present invention relates to a process for the pre-paration of pharmaceutically acceptable alkali metal salts and esters of clavulanic acid, especially potassium clavulanate.
Clavulanic acid and its alkali metal salts and esters are !3-lactamase inhibitors, able to enhance the effectiveness of ~o penicillins and cephalosporins.
Clavulanic acid is normally prepared by the fermentation of a microorganism which produces clavulanic acid as for instance Streptomyces strains such as Streptomyces clavuliQer-us. The resulting aqueous broth is normally subjected to ~s conventional purification and concentration processes, such as disclosed in GB-1508977.
EP-A-26044 discloses the use of the tertiary butylamine salt of clavulanic acid as an useful intermediate in the pre-paration of clavulanic acid. Other amine salts of clavulanic zo acid are disclosed in for example WO 93/25S57, WO 94/22873, EP-A-0387178, EP-A-562583, WO 96/26944 and WO 96/20199. In the present application also diamino ethers as disclosed in the latter application are considered as amines. All these cited references are incorporated in the present application by zs reference.
The aim of this invention is to prepare clavulanic acid and its pharmaceutically acceptable salts, such as potassium, wherein the desired substance is obtained in a high yield and of high purity.
3o A lot of process improvements were surprisingly found.
First of a11, whole broth extraction appears to be an advan-tageous alternative for removing solids from the fermentation broth. A further improvement relates to the application of an amine which forms with clavulanic acid an amine clavulanate, 3s which sticks to the walls in the normally applied ethyl acetate /acetone solution. The addition of a water miscible organic solvent like an alcohol, preferably absolute alcohol, avoids the tendency to stick to the walls of the diamine crystals of the crystallising vessel which results in a yield loss.
Furthermore, it appears to be possible to influence the crys-s tal morphology of the end product by regulating the amount of water added during the crystallisation stage.
According to the present invention a process for the preparation of a pharmaceutically acceptable salt or ester of clavulanic acid has been provided comprising one or more of ~o the following steps:
- fermentation of a clavulanic producing microorganism;
- acidifying the clavulanic acid containing broth;
- optional addition of a small amount of a water miscible solvent;
~s - extraction of the acidified clavulanic acid containing broth with a water immiscible organic solvent;
- concentration of the clavulanic acid containing water immiscible organic solution by evaporation;
- purification of the concentrated clavulanic acid so-zo lution by adsorption;
- filtration of the clavulanic acid solution;
- optional addition of one or more water miscible organic solvent(s);
- addition of an amine, optionally together with a water zs miscible solvent, to prepare a clavulanate salt of said amine;
optional recrystallization of the clavulanate salt of amine formed;
- conversion into purified clavulanic acid by acidifying 30 or into a pharmaceutically acceptable salt or ester clavulanate by adding a source of the corresponding salt or ester;
- separation of the pharmaceutically acceptable salt or ester clavulanate from the solution.
35 This applies for instance to the application of amines especially of N,N,N',N'-tetramethylethylenediamine, 1,3-WO 9$/21212 PCTIEP97/06263 bis(di-methylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethyl-amino)ethyl)ether.
' In almost a11 prior art processes it is emphasized that it should be necessary to remove any of the suspended solids s prior to solvent extraction. Although filtration or ultrafiltration does give favourable results, it turns out that whole broth extraction does give a comparable end result in terms of yield and purity of the end product . An important advantage of leaving out the filtration step is of course a ~o larger process efficiency by leaving out a process step. The possible difficulties of broth instability and emulsion forma-tion can be met by adding a small (up to about 25% of the total volume of the fermentation broth) amount of solvent such as a water miscible ketone or alcohol and/or pH adjustment to is denature proteins in the broth and/or addition of a suitable demulsifier and therefore to improve the whole broth extrac-tion performance.
During the crystallisation stage of the amine clavulanate it has been found advantageous to add a small amount of an zo alcohol like absolute ethanol to the mixture comprising clavu lanic acid and the extracting solvent, preferably ethylacetate and the crystallising solvent, preferably acetone. In a pre-ferred embodiment, the alcohol is added before or simulta-neously with the amine. The application of this three compo-25 nent mixture of solvent diminishes the exhibition of the crystals to stick to the walls resulting in a loss of yield and it also leads surprisingly to an enhancement of the purity and general quality characteristics. A11 ways of addition of the amine to the mixture comprising clavulanic acid result so then in favourable crystallization results, for instance besides addition of the amine to the mixture comprising clavu-lanic acid both simultaneous addition of the amine and the clavulanic acid mixture to a reaction vessel and the addition of clavulanic acid mixture to the amine. Furthermore, 35 recrystallisation can optionally be applied by treating the aqueous solution of amine clavulanate, either neat or partly diluted with solvent, with charcoal and then sterile filtering the resulting solution prior to sterile crystallisation.
During the formation of the potassium clavulanate it has been found advantageous to form the same by slurrying the s amine salt in a solvent, preferably a water miscible ketone or alcohol and then adding a potassium source, preferably potassium ethyl hexanoate in a solvent, also preferably a water miscible ketone or alcohol. Use of a slurry system reduces significantly the amount of solvent required which ~o reduces costs and increases the yield of the endproduct.
Furthermore, it has been found advantageous to add a small amount of water to the (slurry) solvent. Surprisingly it has been found that by doing this it is possible to influence the crystal morphology of the final product. Thus it is possible ~s to obtain crystals which can be washed more readily and which have improved filtration and drying characteristics. In this way it is possible to form either rosette or needle formed crystals, preferably a cluster of needles formed crystals.
Furthermore, especially in case as amine the bis(2-(di zo methylamino)ethyl)ether is applied the residual amine in the endproduct is extremely low, lower than 0.05% w/w, preferably lower than 0.02% w/w appears to be possible, viz. ten times lower than the level of tertiary butylamine permitted by the British Pharmacopoeia. A low amine content in the amine 2s clavulanate intermediate is desirable since it results in a more stable endproduct. Therefore, it is really advantageous to apply potassium clavulanate, prepared in this way, in a pharmaceutical composition comprising potassium clavulanate and amoxycillin trihydrate.
3o The following examples are given for illustration purposes only.
OF CLAW'LANIC ACID
s The present invention relates to a process for the pre-paration of pharmaceutically acceptable alkali metal salts and esters of clavulanic acid, especially potassium clavulanate.
Clavulanic acid and its alkali metal salts and esters are !3-lactamase inhibitors, able to enhance the effectiveness of ~o penicillins and cephalosporins.
Clavulanic acid is normally prepared by the fermentation of a microorganism which produces clavulanic acid as for instance Streptomyces strains such as Streptomyces clavuliQer-us. The resulting aqueous broth is normally subjected to ~s conventional purification and concentration processes, such as disclosed in GB-1508977.
EP-A-26044 discloses the use of the tertiary butylamine salt of clavulanic acid as an useful intermediate in the pre-paration of clavulanic acid. Other amine salts of clavulanic zo acid are disclosed in for example WO 93/25S57, WO 94/22873, EP-A-0387178, EP-A-562583, WO 96/26944 and WO 96/20199. In the present application also diamino ethers as disclosed in the latter application are considered as amines. All these cited references are incorporated in the present application by zs reference.
The aim of this invention is to prepare clavulanic acid and its pharmaceutically acceptable salts, such as potassium, wherein the desired substance is obtained in a high yield and of high purity.
3o A lot of process improvements were surprisingly found.
First of a11, whole broth extraction appears to be an advan-tageous alternative for removing solids from the fermentation broth. A further improvement relates to the application of an amine which forms with clavulanic acid an amine clavulanate, 3s which sticks to the walls in the normally applied ethyl acetate /acetone solution. The addition of a water miscible organic solvent like an alcohol, preferably absolute alcohol, avoids the tendency to stick to the walls of the diamine crystals of the crystallising vessel which results in a yield loss.
Furthermore, it appears to be possible to influence the crys-s tal morphology of the end product by regulating the amount of water added during the crystallisation stage.
According to the present invention a process for the preparation of a pharmaceutically acceptable salt or ester of clavulanic acid has been provided comprising one or more of ~o the following steps:
- fermentation of a clavulanic producing microorganism;
- acidifying the clavulanic acid containing broth;
- optional addition of a small amount of a water miscible solvent;
~s - extraction of the acidified clavulanic acid containing broth with a water immiscible organic solvent;
- concentration of the clavulanic acid containing water immiscible organic solution by evaporation;
- purification of the concentrated clavulanic acid so-zo lution by adsorption;
- filtration of the clavulanic acid solution;
- optional addition of one or more water miscible organic solvent(s);
- addition of an amine, optionally together with a water zs miscible solvent, to prepare a clavulanate salt of said amine;
optional recrystallization of the clavulanate salt of amine formed;
- conversion into purified clavulanic acid by acidifying 30 or into a pharmaceutically acceptable salt or ester clavulanate by adding a source of the corresponding salt or ester;
- separation of the pharmaceutically acceptable salt or ester clavulanate from the solution.
35 This applies for instance to the application of amines especially of N,N,N',N'-tetramethylethylenediamine, 1,3-WO 9$/21212 PCTIEP97/06263 bis(di-methylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethyl-amino)ethyl)ether.
' In almost a11 prior art processes it is emphasized that it should be necessary to remove any of the suspended solids s prior to solvent extraction. Although filtration or ultrafiltration does give favourable results, it turns out that whole broth extraction does give a comparable end result in terms of yield and purity of the end product . An important advantage of leaving out the filtration step is of course a ~o larger process efficiency by leaving out a process step. The possible difficulties of broth instability and emulsion forma-tion can be met by adding a small (up to about 25% of the total volume of the fermentation broth) amount of solvent such as a water miscible ketone or alcohol and/or pH adjustment to is denature proteins in the broth and/or addition of a suitable demulsifier and therefore to improve the whole broth extrac-tion performance.
During the crystallisation stage of the amine clavulanate it has been found advantageous to add a small amount of an zo alcohol like absolute ethanol to the mixture comprising clavu lanic acid and the extracting solvent, preferably ethylacetate and the crystallising solvent, preferably acetone. In a pre-ferred embodiment, the alcohol is added before or simulta-neously with the amine. The application of this three compo-25 nent mixture of solvent diminishes the exhibition of the crystals to stick to the walls resulting in a loss of yield and it also leads surprisingly to an enhancement of the purity and general quality characteristics. A11 ways of addition of the amine to the mixture comprising clavulanic acid result so then in favourable crystallization results, for instance besides addition of the amine to the mixture comprising clavu-lanic acid both simultaneous addition of the amine and the clavulanic acid mixture to a reaction vessel and the addition of clavulanic acid mixture to the amine. Furthermore, 35 recrystallisation can optionally be applied by treating the aqueous solution of amine clavulanate, either neat or partly diluted with solvent, with charcoal and then sterile filtering the resulting solution prior to sterile crystallisation.
During the formation of the potassium clavulanate it has been found advantageous to form the same by slurrying the s amine salt in a solvent, preferably a water miscible ketone or alcohol and then adding a potassium source, preferably potassium ethyl hexanoate in a solvent, also preferably a water miscible ketone or alcohol. Use of a slurry system reduces significantly the amount of solvent required which ~o reduces costs and increases the yield of the endproduct.
Furthermore, it has been found advantageous to add a small amount of water to the (slurry) solvent. Surprisingly it has been found that by doing this it is possible to influence the crystal morphology of the final product. Thus it is possible ~s to obtain crystals which can be washed more readily and which have improved filtration and drying characteristics. In this way it is possible to form either rosette or needle formed crystals, preferably a cluster of needles formed crystals.
Furthermore, especially in case as amine the bis(2-(di zo methylamino)ethyl)ether is applied the residual amine in the endproduct is extremely low, lower than 0.05% w/w, preferably lower than 0.02% w/w appears to be possible, viz. ten times lower than the level of tertiary butylamine permitted by the British Pharmacopoeia. A low amine content in the amine 2s clavulanate intermediate is desirable since it results in a more stable endproduct. Therefore, it is really advantageous to apply potassium clavulanate, prepared in this way, in a pharmaceutical composition comprising potassium clavulanate and amoxycillin trihydrate.
3o The following examples are given for illustration purposes only.
Examples Example 1 Whole broth extraction of a clavulanic acid containing broth Broth resulting from a fermentation with Streptomyces clavuliQerus, (3.5 1, containing 13.3 g of clavulanic acid) was cooled to 2 °C. This broth was added to 10.5 1 ethylaceta-1o to at 1-3 °C while stirring. After addition of the broth, the pH of the mixture was adjusted to pH=1.6 with the aid of 3 M
sulphuric acid. The mixture was rested to settle for 5 min-utes, and the layers were separated. 9.25 1 of ethylacetate layer was collected, containing 7.5 g of clavulanic acid.
' Example 2 Evaporation of clavulanic acid containing ethyl acetate sol-ution The ethylacetate solution (9.25 1) from the preceding example was evaporated in vacuo at 30-35 °C, using a natural circulation evaporator. A concentrated solution (0.88 1) was obtained, containing 7.5 g of clavulanic acid. This solution z5 was concentrated using a rotatory thin film evaporator (va-cuum, 30-35 °C). A concentrate (0.11 1) was obtained, contai-ning 7.4 g of clavulanic acid.
3o Example 3 . Preparation of crystalline bis (2-(dimethylamino)ethyl)ether diclavulanate Into a one litre three-necked roundbottom flask fitted 35 with a thermometer, two dropping funnels and a stirrer was placed ethanol (50 ml). The temperature was brought to 10° C
and under stirring an impure solution of clavulanic acid (400 ml; 32.9 g clavuianic acid/litre) in ethyl acetate and a solution of bis(2-(dimethylamino)ethyl)ether (13.5 g) in ethanol (230 ml) were added simultaneously. The temperature during the addition was maintained between 10-15° C. After the addition (15-20 minutes) , the mixture was stirred for one hour at 5° C. The crystals were filtered, washed twice with ethyl acetate 40 ml) and dried under vacuum at room temperature. 16 g of bis(2-(dimethylamino)ethyl)ether diclavulanate was obtained.
~o Example 4 Purification of clavulanic acid solution by treatment with charcoal The concentrated ethyl acetate solution of example 2 (7.4 g of clavulanic acid in 110 ml) was subjected to a char-coal treatment . The solution was cooled to 5 °C, and charcoal (16.5 g, Norit SX Ultra) was added. The mixture was stirred zo during two hours at 5-10 °C. Filter aid (Dicalite, 5 g) was added, and the mixture was filtered. The solid cake was washed with ethyl acetate until the volume of the collected filtrate was 185 ml.
Example 5 Crystallization of bis(2-(dimethylamino)ethyl)ether diclavulanate from a concentrated clavulanic acid solution in ethyl acetate The following experiment was carried out in nitrogen atmosphere. Absolute ethanol (450 ml) was added to a solution of clavulanic acid in ethyl acetate (900 ml, concentration g of clavulanic acid/litre). The solution was stirred, 35 cooled to 10 °C, and bis(2-(dimethylamino)ethyl)ether (35.l ml, 0.18 moles) was added. The mixture was cooled to 3 °C, and stirred during one hour. The crystal suspension was filtered, and the cake was washed with 200 ml of acetone, and again with 200 ml of acetone. The wet cake was dried in vacuum at room temperature. 45 g of bis (2- (dimethylamino) ethyl) ether diclavulanate was obtained.
Example 6 Crystallization of potassium clavulanate starting from bis(2-(dimethylama.no)ethyl)ether diclavulanate ~o The following experiment was carried out in nitrogen atmosphere. Bis(2-(dimethylamino)ethyl)ether diclavulanate (10 g) was suspended in a mixture of acetone (300 ml) and water (6 ml). The mixture was stirred, cooled to 12 °C, and ~s a solution of potassium 2-ethylhexanoate in acetone (125 ml of a 0.34 M solution) was added in the course of 10 minutes.
The mixture was cooled to 5 °C, and stirred during one hour.
The crystal suspension was filtered and the cake was washed with three cake volumes acetone. The wet cake was dried in zo vacuum at 20 °C. 8.22 g of potassium clavulanate was obtained.
Example 7 Purification of bis(2-(dimethylamino)ethyl)ether diclavulanate zs by recrystallization The following experiment was carried out in nitrogen atmosphere. Bis(2-(dimethylamino)ethyl)ether diclavulanate (10 g) was dissolved in a mixture of absolute ethanol (45 ml) 3o and water (5 ml) at 20 °C. The clear solution was added to acetone (250 ml) in the course of 20 minutes while stirring the mixture at 20 °C. The mixture was cooled to 5 °C, and _ stirred during 30 minutes. The crystal suspension was fil tered, and the cake was washed with 2 cake volumes of acetone .
35 The crystals were dried in vacuum at 20 °C. 9.44 g of bis(2 (dimethylamino)ethyl)ether diclavulanate was obtained.
_ g _ Example 8 Crystallization of potassium clavulanate starting from bis(2-(dimethylamino)ethyl)ether diclavulanate with intermediate charcoal treatment The following experiment was carried out in nitrogen atmosphere.Bis(2-(dimethylamino)ethyl)ether diclavulanate(10 g) was dissolved in a mixture of absolute ethanol (45 ml) and water (5 ml) at 20 °C. The pH of the mixture was adjusted to ~o pH=6.5 with the aid of 2-ethylhexanoic acid. Charcoal (1 g) was added, and the mixture was stirred during 30 minutes.
Filter aid was added (Dicalite, 0.3 g), and the mixture was filtered. The cake was washed with absolute ethanol (5 ml), and acetone (10 ml). The combined filtrates were .added to ~s acetone (250 ml) at 10 °C. A crystal suspension was obtained.
A solution of potassium 2-ethylhexanoate in acetone (125 ml of a 0.34 M solution) was added in the course of 10 minutes.
The mixture was cooled to 5 °C, and stirred during one hour.
The crystal suspension was filtered and the cake was washed zo with three cake volumes of acetone. The wet cake was dried in vacuum at 20 °C. 7.56 g of potassium clavulanate clusters of needles was obtained.
sulphuric acid. The mixture was rested to settle for 5 min-utes, and the layers were separated. 9.25 1 of ethylacetate layer was collected, containing 7.5 g of clavulanic acid.
' Example 2 Evaporation of clavulanic acid containing ethyl acetate sol-ution The ethylacetate solution (9.25 1) from the preceding example was evaporated in vacuo at 30-35 °C, using a natural circulation evaporator. A concentrated solution (0.88 1) was obtained, containing 7.5 g of clavulanic acid. This solution z5 was concentrated using a rotatory thin film evaporator (va-cuum, 30-35 °C). A concentrate (0.11 1) was obtained, contai-ning 7.4 g of clavulanic acid.
3o Example 3 . Preparation of crystalline bis (2-(dimethylamino)ethyl)ether diclavulanate Into a one litre three-necked roundbottom flask fitted 35 with a thermometer, two dropping funnels and a stirrer was placed ethanol (50 ml). The temperature was brought to 10° C
and under stirring an impure solution of clavulanic acid (400 ml; 32.9 g clavuianic acid/litre) in ethyl acetate and a solution of bis(2-(dimethylamino)ethyl)ether (13.5 g) in ethanol (230 ml) were added simultaneously. The temperature during the addition was maintained between 10-15° C. After the addition (15-20 minutes) , the mixture was stirred for one hour at 5° C. The crystals were filtered, washed twice with ethyl acetate 40 ml) and dried under vacuum at room temperature. 16 g of bis(2-(dimethylamino)ethyl)ether diclavulanate was obtained.
~o Example 4 Purification of clavulanic acid solution by treatment with charcoal The concentrated ethyl acetate solution of example 2 (7.4 g of clavulanic acid in 110 ml) was subjected to a char-coal treatment . The solution was cooled to 5 °C, and charcoal (16.5 g, Norit SX Ultra) was added. The mixture was stirred zo during two hours at 5-10 °C. Filter aid (Dicalite, 5 g) was added, and the mixture was filtered. The solid cake was washed with ethyl acetate until the volume of the collected filtrate was 185 ml.
Example 5 Crystallization of bis(2-(dimethylamino)ethyl)ether diclavulanate from a concentrated clavulanic acid solution in ethyl acetate The following experiment was carried out in nitrogen atmosphere. Absolute ethanol (450 ml) was added to a solution of clavulanic acid in ethyl acetate (900 ml, concentration g of clavulanic acid/litre). The solution was stirred, 35 cooled to 10 °C, and bis(2-(dimethylamino)ethyl)ether (35.l ml, 0.18 moles) was added. The mixture was cooled to 3 °C, and stirred during one hour. The crystal suspension was filtered, and the cake was washed with 200 ml of acetone, and again with 200 ml of acetone. The wet cake was dried in vacuum at room temperature. 45 g of bis (2- (dimethylamino) ethyl) ether diclavulanate was obtained.
Example 6 Crystallization of potassium clavulanate starting from bis(2-(dimethylama.no)ethyl)ether diclavulanate ~o The following experiment was carried out in nitrogen atmosphere. Bis(2-(dimethylamino)ethyl)ether diclavulanate (10 g) was suspended in a mixture of acetone (300 ml) and water (6 ml). The mixture was stirred, cooled to 12 °C, and ~s a solution of potassium 2-ethylhexanoate in acetone (125 ml of a 0.34 M solution) was added in the course of 10 minutes.
The mixture was cooled to 5 °C, and stirred during one hour.
The crystal suspension was filtered and the cake was washed with three cake volumes acetone. The wet cake was dried in zo vacuum at 20 °C. 8.22 g of potassium clavulanate was obtained.
Example 7 Purification of bis(2-(dimethylamino)ethyl)ether diclavulanate zs by recrystallization The following experiment was carried out in nitrogen atmosphere. Bis(2-(dimethylamino)ethyl)ether diclavulanate (10 g) was dissolved in a mixture of absolute ethanol (45 ml) 3o and water (5 ml) at 20 °C. The clear solution was added to acetone (250 ml) in the course of 20 minutes while stirring the mixture at 20 °C. The mixture was cooled to 5 °C, and _ stirred during 30 minutes. The crystal suspension was fil tered, and the cake was washed with 2 cake volumes of acetone .
35 The crystals were dried in vacuum at 20 °C. 9.44 g of bis(2 (dimethylamino)ethyl)ether diclavulanate was obtained.
_ g _ Example 8 Crystallization of potassium clavulanate starting from bis(2-(dimethylamino)ethyl)ether diclavulanate with intermediate charcoal treatment The following experiment was carried out in nitrogen atmosphere.Bis(2-(dimethylamino)ethyl)ether diclavulanate(10 g) was dissolved in a mixture of absolute ethanol (45 ml) and water (5 ml) at 20 °C. The pH of the mixture was adjusted to ~o pH=6.5 with the aid of 2-ethylhexanoic acid. Charcoal (1 g) was added, and the mixture was stirred during 30 minutes.
Filter aid was added (Dicalite, 0.3 g), and the mixture was filtered. The cake was washed with absolute ethanol (5 ml), and acetone (10 ml). The combined filtrates were .added to ~s acetone (250 ml) at 10 °C. A crystal suspension was obtained.
A solution of potassium 2-ethylhexanoate in acetone (125 ml of a 0.34 M solution) was added in the course of 10 minutes.
The mixture was cooled to 5 °C, and stirred during one hour.
The crystal suspension was filtered and the cake was washed zo with three cake volumes of acetone. The wet cake was dried in vacuum at 20 °C. 7.56 g of potassium clavulanate clusters of needles was obtained.
Claims (14)
1. A process for the preparation of a pharmaceutically acceptable salt or ester of clavulanic acid or for the isolation of clavulanic acid consisting essentially of the following steps:
- fermentation of a clavulanic producing microorganism;
- acidifying the clavulanic acid containing broth;
- optional addition of a small amount of a water miscible solvent;
- extraction of the acidified clavulanic acid containing broth with a water immiscible organic solvent;
- concentration of the clavulanic acid containing water immiscible organic solvent by evaporation;
- purification of the concentrated clavulanic acid solution by treatment with charcoal;
- filtration of the clavulanic acid solution;
- optional addition of one or more water miscible organic solvent (s);
- addition of an amine optionally together with a water miscible solvent to prepare a clavulanate salt of said amine;
- optional recrystallization of the clavulanate salt of amine formed;
conversion into purified clavulanic acid by acidifying or into a pharmaceutically acceptable salt or ester clavulanate by adding a source of the corresponding salt or ester;
- separation of the clavulanic acid or pharmaceutically acceptable salt or ester clavulanate from the solution, characterized by carrying out the conversion of the clavulanate salt of amine into a clavulanate of a pharmaceutically acceptable salt or ester or into clavulanic acid in a slurry system by slurrying the amine clavulanate in a slurrying solvent if necessary and contacting the same with a pharmaceutically acceptable salt or ester forming compound or with an acid.
- fermentation of a clavulanic producing microorganism;
- acidifying the clavulanic acid containing broth;
- optional addition of a small amount of a water miscible solvent;
- extraction of the acidified clavulanic acid containing broth with a water immiscible organic solvent;
- concentration of the clavulanic acid containing water immiscible organic solvent by evaporation;
- purification of the concentrated clavulanic acid solution by treatment with charcoal;
- filtration of the clavulanic acid solution;
- optional addition of one or more water miscible organic solvent (s);
- addition of an amine optionally together with a water miscible solvent to prepare a clavulanate salt of said amine;
- optional recrystallization of the clavulanate salt of amine formed;
conversion into purified clavulanic acid by acidifying or into a pharmaceutically acceptable salt or ester clavulanate by adding a source of the corresponding salt or ester;
- separation of the clavulanic acid or pharmaceutically acceptable salt or ester clavulanate from the solution, characterized by carrying out the conversion of the clavulanate salt of amine into a clavulanate of a pharmaceutically acceptable salt or ester or into clavulanic acid in a slurry system by slurrying the amine clavulanate in a slurrying solvent if necessary and contacting the same with a pharmaceutically acceptable salt or ester forming compound or with an acid.
2. A process according to claim 1, characterized by adding a small amount of water to the slurrying solvent.
3. A process according to claims 1 or 2 wherein as amine any one of the amines N,N,N',N'-tetramethylethyleendi-amine, 1,3-bis(dimethylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethylamino)ethyl)ether is applied.
4. A process according to anyone of the claims 1 - 3, wherein solids are removed from the clavulanic acid containing fermentation broth before extraction.
5. A process according to anyone of the claims 1 - 4, characterized by the addition of a water miscible ketone and/or alcohol to the fermentation broth.
6. A process according to anyone of the claims 1 - 5, characterized by extraction of the acidified clavulanic acid containing broth with ethylacetate.
7. A process according to anyone of the claims 1 - 6, characterized by the addition of the water miscible solvent acetone to the clavulanic acid solution after the purification and filtration steps.
8. A process according to anyone of the claims 1 - 7, characterized by the addition of the water miscible solvent ethanol to the solution comprising clavulanic acid, before or simultaneous with the addition of the amine to prepare a clavulanate salt of the amine.
9. A process according to claim 8, characterized by simultaneous addition of the amine and the solution comprising clavulanic acid to a reaction vessel.
10. A process according to claim 8, characterized by the addition of the solution comprising clavulanic acid to the amine.
11. A process according to anyone of the claims 1 - 10, characterized by recrystallization of said amine clavulanate in a mixture of ethanol and water, optional treatment with charcoal and crystallisation by the addition of acetone.
12. A process for the preparation of potassium clavulanate, consisting essentially of the following steps:
- fermentation of Streptomyces clavuligerus to produce clavulanic acid;
- acidifying the clavulanic acid containing broth to a pH
between 1 and 3 by addition of a concentrated acid solution;
- optional removing of solids from the fermentation broth;
- optional addition of a small amount of a water miscible ketone or alcohol;
- extraction of the acidified clavulanic acid containing broth with ethylacetate;
- concentration of the clavulanic acid containing ethylacetate solution by evaporation;
- purification of said solution by treatment with charccal;
- filtration of the resulting clavulanic acid solution;
- optional addition of acetone;
- addition of ethanol and anyone of the amines N,N,N',N'-tetramethylethyleendiamine, 1,3-bis(di-methylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethylamino)ethyl)ether;
- optional recrystallisation of the amine clavulanate formed by dissolution of the same in a mixture of ethanol and water, optional treatment with charcoal, and crystallisation in acetone;
- conversion into potassium clavulanate by adding potassium ethylhexanoate;
- isolation of potassium clavulanate from the slurry, characterized by carrying out the conversion of the clavulanate salt of amine into potassium clavulanate in a slurry system and contacting the same with potassium ethylhexanoate in a water miscible ketone or alcohol.
- fermentation of Streptomyces clavuligerus to produce clavulanic acid;
- acidifying the clavulanic acid containing broth to a pH
between 1 and 3 by addition of a concentrated acid solution;
- optional removing of solids from the fermentation broth;
- optional addition of a small amount of a water miscible ketone or alcohol;
- extraction of the acidified clavulanic acid containing broth with ethylacetate;
- concentration of the clavulanic acid containing ethylacetate solution by evaporation;
- purification of said solution by treatment with charccal;
- filtration of the resulting clavulanic acid solution;
- optional addition of acetone;
- addition of ethanol and anyone of the amines N,N,N',N'-tetramethylethyleendiamine, 1,3-bis(di-methylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethylamino)ethyl)ether;
- optional recrystallisation of the amine clavulanate formed by dissolution of the same in a mixture of ethanol and water, optional treatment with charcoal, and crystallisation in acetone;
- conversion into potassium clavulanate by adding potassium ethylhexanoate;
- isolation of potassium clavulanate from the slurry, characterized by carrying out the conversion of the clavulanate salt of amine into potassium clavulanate in a slurry system and contacting the same with potassium ethylhexanoate in a water miscible ketone or alcohol.
13. A process according to claim 12, characterized by adding a small amount of water to the slurrying solvent.
14. Pharmaceutical composition comprising potassium clavulanate as prepared according to anyone of the claims 1 - 13, and amoxycillin trihydrate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96203117.5 | 1996-11-11 | ||
| EP96203117 | 1996-11-11 | ||
| PCT/EP1997/006263 WO1998021212A1 (en) | 1996-11-11 | 1997-11-10 | Process for the preparation of salts and esters of clavulanic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2271847A1 true CA2271847A1 (en) | 1998-05-22 |
Family
ID=8224563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002271847A Abandoned CA2271847A1 (en) | 1996-11-11 | 1997-11-10 | Process for the preparation of salts and esters of clavulanic acid |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0937084A1 (en) |
| JP (1) | JP2001503763A (en) |
| CN (1) | CN1238776A (en) |
| AU (1) | AU5551698A (en) |
| BR (1) | BR9713339A (en) |
| CA (1) | CA2271847A1 (en) |
| NO (1) | NO992225L (en) |
| PL (1) | PL333247A1 (en) |
| TR (1) | TR199901631T2 (en) |
| WO (1) | WO1998021212A1 (en) |
| ZA (1) | ZA9710141B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT400033B (en) | 1992-03-10 | 1995-09-25 | Biochemie Gmbh | NEW METHOD FOR ISOLATING AND PURIFYING CLAVULANIC ACID AND FOR PRODUCING PHARMACOLOGICALLY COMPATIBLE SALTS THEREOF |
| SI9500134B (en) * | 1995-04-20 | 2004-04-30 | Lek, | Preparation procedure of pure alkali salts of clavulanic acid |
| AT403375B (en) * | 1995-11-15 | 1998-01-26 | Biochemie Gmbh | METHOD FOR FILLING ALKALINE SALTS OF CLAVULANIC ACID |
| EP1095046A1 (en) * | 1998-07-16 | 2001-05-02 | Dsm N.V. | Improved process for the preparation of salts and esters of clavulanic acid |
| SI1165049T2 (en) | 1999-04-01 | 2011-11-30 | Dsm Ip Assets Bv | Agglomerates by crystallisation |
| DK1284978T4 (en) * | 2000-05-13 | 2009-01-05 | Smithkline Beecham Plc | Process for purifying a salt of clavulanic acid |
| WO2008065160A1 (en) * | 2006-12-01 | 2008-06-05 | Dsm Ip Assets B.V. | Process for the production of clavulanic acid |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9300296B (en) * | 1992-06-11 | 1998-06-30 | Smithkline Beecham P.L.C. | Process and intermediates for the preparation of clavulanic acid |
| KR100200239B1 (en) * | 1992-10-21 | 1999-06-15 | 김충환 | Process for preparing salts of clavulanic acid |
| GB9305565D0 (en) * | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Novel compounds and processes |
| SI9400107A (en) * | 1994-03-02 | 1995-10-31 | Lek Tovarna Farmacevtskih | New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804. |
| GB9426261D0 (en) * | 1994-12-24 | 1995-02-22 | Spurcourt Ltd | Clavulanic acid salts |
| SI9500074A (en) * | 1995-03-10 | 1996-10-31 | Lek Tovarna Farmacevtskih | Process for preparation of alkani salts of clavulanic acid. |
| SI9500134B (en) * | 1995-04-20 | 2004-04-30 | Lek, | Preparation procedure of pure alkali salts of clavulanic acid |
| KR100200242B1 (en) * | 1995-05-16 | 1999-06-15 | 김충환 | Process for preparing clavulanic acid salt |
-
1997
- 1997-11-10 EP EP97951881A patent/EP0937084A1/en not_active Withdrawn
- 1997-11-10 WO PCT/EP1997/006263 patent/WO1998021212A1/en not_active Application Discontinuation
- 1997-11-10 PL PL97333247A patent/PL333247A1/en unknown
- 1997-11-10 CN CN97180163A patent/CN1238776A/en active Pending
- 1997-11-10 CA CA002271847A patent/CA2271847A1/en not_active Abandoned
- 1997-11-10 AU AU55516/98A patent/AU5551698A/en not_active Abandoned
- 1997-11-10 TR TR1999/01631T patent/TR199901631T2/en unknown
- 1997-11-10 BR BR9713339-6A patent/BR9713339A/en not_active Application Discontinuation
- 1997-11-10 JP JP52216798A patent/JP2001503763A/en active Pending
- 1997-11-11 ZA ZA9710141A patent/ZA9710141B/en unknown
-
1999
- 1999-05-07 NO NO992225A patent/NO992225L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA9710141B (en) | 1998-06-25 |
| NO992225D0 (en) | 1999-05-07 |
| AU5551698A (en) | 1998-06-03 |
| TR199901631T2 (en) | 1999-09-21 |
| BR9713339A (en) | 2000-05-09 |
| NO992225L (en) | 1999-05-07 |
| WO1998021212A1 (en) | 1998-05-22 |
| CN1238776A (en) | 1999-12-15 |
| EP0937084A1 (en) | 1999-08-25 |
| JP2001503763A (en) | 2001-03-21 |
| PL333247A1 (en) | 1999-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0672669B1 (en) | Process for the preparation of potassium clavulanate | |
| JP5184465B2 (en) | Method for producing potassium clavulanate | |
| US4222942A (en) | Isolation of organic acids | |
| EP0813536B1 (en) | Process for the preparation of pharmaceutically acceptable salts of clavulanic acid | |
| CA2271847A1 (en) | Process for the preparation of salts and esters of clavulanic acid | |
| RU2166506C2 (en) | Method of synthesis and/or purification of clavulanic acid or its pharmaceutically acceptable salt or ester and method of its separation from impurity of clavam-2-carboxylic acid containing in filtered off fermentation broth | |
| US4456753A (en) | Process for the manufacture of highly crystalline sodium cefoperazone | |
| EP0729961B1 (en) | Clavulanic acid salt | |
| US6417352B1 (en) | Process for the isolation of a pharmaceutically acceptable alkali metal salt of clavulanic acid | |
| EP0941229B1 (en) | Purification of fermented clavulanic acid | |
| WO2000004028A1 (en) | Improved process for the preparation of salts and esters of clavulanic acid | |
| MXPA99004322A (en) | Process for the preparation of salts and esters of clavulanic acid | |
| WO1998042858A1 (en) | Process for the isolation of a pharmaceutically acceptable alkali metal salt of clavulanic acid | |
| US20010029038A1 (en) | Purification of fermented clavulanic acid | |
| RU2522806C1 (en) | Improved method of purification of pravastatin | |
| AU692091C (en) | Preparation of clavulanate salts | |
| GB2298201A (en) | Clavulanic acid benzhydrylamine salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20031110 |